2024 Laboratory Reimbursement Trends and What to Expect in 2025
Revenue cycle management experts weigh in on the biggest developments of 2024 and how labs can best prepare for 2025 and beyond
Keep up to date on the latest legal, compliance, and business developments affecting the lab industry, while offering analysis and insight to ensure your lab’s success.
Revenue cycle management experts weigh in on the biggest developments of 2024 and how labs can best prepare for 2025 and beyond
Biden administration blames the decision on Congress’ failure to provide the additional funding necessary to keep the program going.
It remains far from clear whether the new surprise billing rule goes far enough to fix the problem of insurers having too much power in disputes.
In a move to expand access to lab testing for monkeypox, HHS has authorized the FDA to issue EUAs for in vitro diagnostic tests for the virus.
On August 21, the FDA proposed new guidelines on charging for investigational drugs; here are the key highlights.
Revised final rule essentially disarms the threat of insurers having the advantage in out-of-network price disputes.
While the overall M&A market has been slow in 2022, Labcorp has been on a bit of an acquisitions binge.
In a surprise move, the e-retail giant announced it will close down its Amazon Care Primary Health Services for employees at the end of 2022.
While the rule is not yet final, it’s likely that labs will have to pay more in direct CLIA compliance expenses, starting in October.
While not nearly as robust as a year ago, diagnostic companies’ revenues held up surprisingly well in Q2 2022.
Completing the Advance Beneficiary Notice of Noncoverage form can be extremely complex; this guide helps simplify the process.